Caraphenol A

Caraphenol A is a resveratrol trimer and is able to transiently reduce interferon-induced transmembrane (IFITM) protein expression. Caraphenol A safely enhances lentiviral vector gene delivery to hematopoietic stem and progenitor cells^[1]. Caraphenol A also inhibits human cystathionine β-synthase (hCBS) and human cystathionine γ- lyase (hCSE) with IC₅₀s of 5.9 μM and 12.1 μM, respectively^[2]. IC50 & Target:IFITM2, IFITM3^[1]
IC50: 5.9 μM (hCBS), 12.1 μM (hCSE)^[2] In Vitro:Caraphenol A (0-50 μM; 8 h) enhances lentiviral vector (LV) gene delivery to HeLa, but not HEK293T cells^[1].
Caraphenol A decreases interferon induced transmembrane protein-mediated restriction in an endosomal trafficking dependent manner^[1].
Caraphenol A treatment significantly improves hematopoietic stem cell (HSC) gene delivery at both low and high LV doses without altering LV integration patterns^[1].
Caraphenol A (30 μM; 6 h) treatment facilitates lentiviral escape from endosomes^[1].
Caraphenol A (30 μM; 4 h) alters expression and subcellular localization of IFITM2/3 protein and late endosomes in HeLa cells. The effect on late endosome is dependent on IFITM3 expression^[1]. In Vivo:Caraphenol A-treated (30 μM; pretreated for 4 h) HSCs maintain improved gene marking in mice without altering lentiviral integration profiles^[1].